A novel interaction of nucleophosmin with BCL2-associated X protein regulating death evasion and drug sensitivity in human hepatoma cells

Hepatology

Volumn 57, Issue 5, 2013, Pages 1893-1905

  Lo, Shao Jung ^a   Fan, Li Ching ^a   Tsai, Yow Fu ^b   Lin, Kuo Yang ^a   Huang, Hsiao Ling ^a   Wang, Tong Hong ^a   Liu, Hsuan ^c   Chen, Tse Chin ^a   Huang, Shiu Fen ^d   Chang, Chee Jen ^c   Lin, Yu Jr ^c   Yung, Benjamin Yat Ming ^c,e   Hsieh, Sen Yung ^a,f  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^f CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; LAPATINIB; MITOMYCIN; NUCLEOPHOSMIN; PROTEIN BAK; PROTEIN P53; SORAFENIB;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DRUG SENSITIVITY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; MITOCHONDRION; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; ULTRAVIOLET IRRADIATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOCHONDRIA, LIVER; MUTATION; NUCLEAR PROTEINS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84876738157     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26209     Document Type: Article

References (33)

1. Schattenberg JM, Schuchmann M, Galle PR. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol 2011; 26( Suppl. 1): 213-219.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
3. Kelly GL, Strasser A. The essential role of evasion from cell death in cancer. Adv Cancer Res 2011; 111: 39-96.
4. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005.
5. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 30: 35-51.
6. Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, et al. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009; 15: 5895-5901.
7. Hsieh SY, Hsu CY, He JR, Liu CL, Lo SJ, Chen YC, et al. Identifying apoptosis-evasion proteins/pathways in human hepatoma cells via induction of cellular hormesis by UV irradiation. J Proteome Res 2009; 8: 3977-3986.
8. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56: 379-390.
9. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000; 103: 127-140.
10. Li Z, Hann SR. The Myc-nucleophosmin-ARF network: a complex web unveiled. Cell Cycle 2009; 8: 2703-2707.
11. Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol 2005; 7: 823-830.
12. Pianta A, Puppin C, Franzoni A, Fabbro D, Di Loreto C, Bulotta S, et al. Nucleophosmin is overexpressed in thyroid tumors. Biochem Biophys Res Commun 2010; 397: 499-504.
13. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6: 493-505.
14. Naoe T, Suzuki T, Kiyoi H, Urano T. Nucleophosmin: a versatile molecule associated with hematological malignancies. Cancer Sci 2006; 97: 963-969.
15. Li Z, Boone D, Hann SR. Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation. Proc Natl Acad Sci U S A 2008; 105: 18794-18799.
16. Yung BY. Oncogenic role of nucleophosmin/B23. Chang Gung Med J 2007; 30: 285-293.
17. Okada M, Jang SW, Ye K. Ebp1 association with nucleophosmin/B23 is essential for regulating cell proliferation and suppressing apoptosis. J Biol Chem 2007; 282: 36744-36754.
18. Dhar SK, St Clair DK. Nucleophosmin blocks mitochondrial localization of p53 and apoptosis. J Biol Chem 2009; 284: 16409-16418.
19. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002; 4: 529-533.
20. Thompson J, Finlayson K, Salvo-Chirnside E, MacDonald D, McCulloch J, Kerr L, et al. Characterisation of the Bax-nucleophosmin interaction: the importance of the Bax C-terminus. Apoptosis 2008; 13: 394-403.
21. Hsieh SY, Liaw SF, Lee SN, Hsieh PS, Lin KH, Chu CM, et al. Aberrant caspase-activated DNase (CAD) transcripts in human hepatoma cells. Br J Cancer 2003; 88: 210-216.
22. Hsieh SY, He JR, Hsu CY, Chen WJ, Bera R, Lin KY, et al. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma. HEPATOLOGY 2011; 53: 504-516.
23. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990; 87: 1973-1977.
24. Stahler F, Roemer K. Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53. Oncogene 1998; 17: 3507-3512.
25. Li J, Zhang X, Sejas DP, Pang Q. Negative regulation of p53 by nucleophosmin antagonizes stress-induced apoptosis in human normal and malignant hematopoietic cells. Leuk Res 2005; 29: 1415-1423.
26. Hsieh SY, Zhuang FH, Wu YT, Chen JK, Lee YL. Profiling the proteome dynamics during the cell cycle of human hepatoma cells. Proteomics 2008; 8: 2872-2884.
27. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006; 3: 995-1000.
28. Kerr LE, Birse-Archbold JL, Short DM, McGregor AL, Heron I, Macdonald DC, et al. Nucleophosmin is a novel Bax chaperone that regulates apoptotic cell death. Oncogene 2007; 26: 2554-2562.
29. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9: 95-107.
30. Hrstka R, Coates PJ, Vojtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 2009; 13: 440-453.
31. Li J, Zhang X, Sejas DP, Bagby GC, Pang Q. Hypoxia-induced nucleophosmin protects cell death through inhibition of p53. J Biol Chem 2004; 279: 41275-41279.
32. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2011; 2: 466-474.
33. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009; 64: 777-783.